BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 31823040)

  • 21. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
    Tan VH; Wilton SB; Kuriachan V; Sumner GL; Exner DV
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):164-70. PubMed ID: 24446023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study.
    Gunten SV; Theuns DA; Kühne M; Reichlin T; Sticherling C; Schaer B
    Cardiol J; 2019; 26(6):711-716. PubMed ID: 30484267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention.
    Peterson PN; Varosy PD; Heidenreich PA; Wang Y; Dewland TA; Curtis JP; Go AS; Greenlee RT; Magid DJ; Normand SL; Masoudi FA
    JAMA; 2013 May; 309(19):2025-34. PubMed ID: 23677314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.
    Probst V; Boveda S; Sadoul N; Marquié C; Chauvin M; Mondoly P; Gras D; Jacon P; Defaye P; Leclercq C; Anselme F
    Arch Cardiovasc Dis; 2020 May; 113(5):359-366. PubMed ID: 32334981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR.
    Kramer DB; Kennedy KF; Noseworthy PA; Buxton AE; Josephson ME; Normand SL; Spertus JA; Zimetbaum PJ; Reynolds MR; Mitchell SL
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):488-97. PubMed ID: 23759471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single- Versus Dual-Chamber Implantable Cardioverter-Defibrillator for Primary Prevention of Sudden Cardiac Death in the United States.
    Margolis G; Hamuda N; Kobo O; Elbaz Greener G; Amir O; Homoud M; Madias C; Heist EK; Ruskin JN; Kazatsker M; Roguin A; Leshem E; Rozen G
    J Am Heart Assoc; 2023 Aug; 12(15):e029126. PubMed ID: 37522389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator.
    Goldenberg I; Erath JW; Russo AM; Burch AE; Assmus B; Bonderman D; McNitt S; Kutyifa V
    Heart Rhythm; 2021 Mar; 18(3):404-410. PubMed ID: 33248269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?
    Botto GL; Forleo GB; Capucci A; Solimene F; Vado A; Bertero G; Palmisano P; Pisanò E; Rapacciuolo A; Infusino T; Vicentini A; Viscusi M; Ferrari P; Talarico A; Russo G; Boriani G; Padeletti L; Lovecchio M; Valsecchi S; D'Onofrio A;
    Europace; 2017 Nov; 19(11):1826-1832. PubMed ID: 28011803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The subcutaneous implantable cardioverter-defibrillator: A tertiary center experience.
    Khazen C; Magnusson P; Flandorfer J; Schukro C
    Cardiol J; 2019; 26(5):543-549. PubMed ID: 29718532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator.
    Adduci C; Palano F; Silvetti G; Cosentino P; Francia P
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):291-297. PubMed ID: 32519207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes after event-free cardioverter defibrillator implantation: comparison between patients discharged within 24 h and routinely hospitalized patients in the German DEVICE registry.
    Spitzer SG; Andresen D; Kuck KH; Seidl K; Eckardt L; Ulbrich M; Brachmann J; Gonska BD; Hoffmann E; Bauer A; Hochadel M; Senges J
    Europace; 2017 Jun; 19(6):968-975. PubMed ID: 27353325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
    Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
    Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial.
    Thomas G; Choi DY; Doppalapudi H; Richards M; Iwai S; Daoud EG; Houmsse M; Kanagasundram AN; Mainigi SK; Lubitz SA; Cheung JW
    J Cardiovasc Electrophysiol; 2019 Oct; 30(10):1994-2001. PubMed ID: 31328298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.